概要
Join us as at the DIA Japan Annual Meeting 2019, to discuss these topics and the future of healthcare.
At DIA, we are here to continue challenging by exerting leadership with a collaboration among industry, government and academia to create a new value in pharmaceutical and medical device development. Needless to say, how to work effectively together is as important as the individual leadership. By maintaining ethics, transparency and fairness, avoiding the conflict of interest and enabling the synergism, a better rational collaboration can be achieved. As a result, our goal is to provide rational medicine with breakthrough innovation to all the current and future people. The 16th DIA Japan Annual Meeting, with a theme of “In Order to Deliver Rational Medicine to all the people in the world,” is a place for discussion, thinking and opinion exchange to contribute to medical environment in the future.
We look forward to welcoming you at Tokyo Big Sight from November 10-12, 2019 for stimulating discussions around promoting better collaboration to drive global health and innovation in this era of medical and scientific transformation.
プログラム委員会
-
Tatsuya Kondo, MD, PhD President
SH Medical Excellence JAPAN, Japan -
Takashi Sato, MSc, PMP
PM Orchestra Takashi Sato, Japan -
Hiroya Asou, MD, PhD, MBA Senior Medical Advisor, Global Patient Safety Japan
Eli Lilly Japan K.K., Japan -
Noriko Fujiwara, MS, RN Certified nurse specialist in Cancer Nursing
IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan -
Yoshikata Furuya, MSc Manager, General Affairs Division
Sankeien Hoshoukai Foundation, Japan -
Toshinori Higashi, PhD Vice President, Regulatory Science
KAKEN PHARMACEUTICAL CO.,LTD., Japan -
Kazuo Ichikawa, PhD, PMP yyy
Xxx, Japan -
Katsuhiko Ichimaru Review Director, Office of New Drug IV
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Toshiko Ishibashi, PhD, RN Oncology Medical Science Department, Medical Affairs Division
Daiichi Sankyo Co., Ltd., Japan -
Yoichi M. Ito, PhD Director
Hokkaido University Hospital, Institute of Health Science Innovation, Japan -
Miyuki Kaneko Japan Regulatory Portfolio Lead, Regulatory Affairs
Pfizer R&D Japan G.K., Japan -
Yoko Kazami, RPh, PMP Director, Regulatory Affairs
Nobelpharma Co., Ltd., Japan -
Noriatsu Kono, MPharm Organizational management
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Arisa Maeda CMC Regulatory Affairs, Regulatory Affairs Area, Japan Development
MSD K.K., Japan -
Noriaki Nagao, MPharm, PMP Pharmaceutical Division,Clinical Development Dept.
JAPAN TOBACCO INC., Japan -
Motohide Nishi, MBA Japan Site Leader & VP Professional Services
Medidata Solutions K.K., Japan -
Minori Niso Brand Marketing Director, APAC Marketing
Parexel, Japan -
Hiromi Okabe, PhD Immunology, Regulatory Affairs Japan,Global Drug Development Division
Novartis Pharma K.K, Japan -
Hiroshi Sakaguchi Deputy Review Director, Office of New Drug I
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Norio Shimazaki Director, Regional Clinical Operations Japan, Korea and Taiwan
Bristol-Myers Squibb K.K., Japan -
Mikiko Shitara Senior Manager, Regulatory Affairs Dept.
Alexionpharma GK, Japan -
Kuniko Shoji Vice-Dean, School of Health Innovation
Kanagawa University of Human Services, Japan -
Keiko Tsumori, MSc Associate Director, Medical Writing, Regulatory Affairs Area, Japan Development
MSD K.K., Japan -
Tadashi Urashima, PhD Performance and Digital Analytics Lead, Medical & Development Excellence Japan
GlaxoSmithKline K.K., Japan -
Manami Yoshida, DVM Associate Director, Medical Affairs – HIV & COVID-19
Gilead Sciences K.K., Japan -
Koichiro Yuji, MD, PhD, FACP Project Associate Professor, The Institute of Medical Science
Japan -
Kazuhiro Kanmuri, PhD Vice President, Product Development and Clinical Operations
Ascent Development Services Inc, Japan -
Kazumichi Kobayashi, RPh Executive Deputy President (Board Member)
Otsuka Medical Devices Co., Ltd., Japan -
Junichi Nishino, MSc, RPh Head, Regulatory Affairs Department
Otsuka Pharmaceutical Co., Ltd., Japan -
Hironobu Saito, PhD Specially Appointed Professor
Tottori University, Chromosome Egineering Research Center, Japan -
Junko Sato, PhD Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Eri Sekine Executive Vice President
CMIC Group, Japan -
Atsushi Tsukamoto, PhD, MSc Head is Therapeutic Area Strategies
Daiichi Sankyo, United States